Optimi Health Corp. IPO - What You Need to Know (U.S. Edition!)

Thinking about investing in Optimi Health Corp.? Here is what you need to know before you put your hard-earned money on the line.

Optimi already trades in Canada under the ticker OPTI and on the U.S. over-the-counter (OTC) market under OPTHF. Now, they are trying to step up to the big leagues by joining the U.S. Nasdaq exchange under the ticker OPTH.

Let’s break down the business, the numbers, and the risks.

1. What does this company actually do?

Optimi operates a high-tech pharmaceutical mushroom farm and processing lab in British Columbia, Canada.

Unlike many of their rivals who only do research, Optimi has a head start in actual production. The Canadian government has licensed them to grow, process, and export medical-grade magic mushrooms (psilocybin) and MDMA.

Instead of running expensive clinical trials or opening their own clinics, Optimi acts as a supplier. They sell raw ingredients and finished drugs to other businesses. Currently, they ship prescription products to Australia for psychiatrists treating PTSD and severe depression, and they supply Canadian patients through a special government access program.

2. How do they make money?

Optimi is still in its very early stages, and its business model is undergoing a major shift.

• The Plan: They want to sell medical-grade psychedelics to researchers and legal international markets. To boost their profit margins, they are completely shutting down their wellness supplement business to focus 100% on high-margin medical drugs.
• The Financial Reality: Right now, they are very small and losing a lot of money. For the year ending September 30, 2025, they brought in just C$426,301 (about US$306,000) in sales, but posted a massive net loss of C$3.7 million (about US$2.7 million). In the three months following that, they lost another C$1.5 million (about US$1.1 million). Simply put, their running costs are vastly outpacing their sales.

3. What is the big news with this U.S. IPO?

Optimi is launching this U.S. IPO to get listed on the Nasdaq.

• The Reverse Split: To meet Nasdaq's strict $4.00 minimum share price rule, Optimi will execute a reverse stock split right before joining. This merges their existing ~96.8 million shares into a smaller, higher-priced pool (think of it like swapping ten $1 bills for one $10 bill). This artificially raises the share price but does not change the actual value of the company.
• Where the money goes: The company didn't provide a highly detailed, line-by-line breakdown of how they will spend the IPO cash in their filing, but they did share the big picture. They plan to use the funds to boost their production capacity in British Columbia and fund their expansion into Israel and eventually the U.S.

4. What are the main risks?

Investing in early-stage psychedelic companies is highly speculative. Here are the major red flags you need to watch out for:

• The Cash Crunch (A Major Warning Sign): Optimi desperately needs this IPO cash to survive. As of September 30, 2025, they had only C$1.8 million (about US$1.3 million) in cash and quick assets, but they owed C$8.5 million (about US$6.2 million) in bills due within a year. That is a C$6.7 million shortfall. Without a successful IPO or another cash injection, they face an immediate financial crisis and could go out of business.
• The U.S. Roadblock & Quotas: Optimi cannot sell its products in the U.S. yet. They need FDA approval first. On top of that, the U.S. government strictly limits how much of these controlled substances can enter the country, which could severely cap their future sales.
• The "Middleman" Risk: Because Optimi doesn't run its own clinical trials, they rely entirely on other companies to do the research and buy their products. If those partner companies run out of money or fail their trials, Optimi won't have anyone to sell to.
• Lawsuit Risks: Dealing with powerful psychoactive substances carries a high risk of lawsuits if a patient has a bad reaction or if a batch of product is contaminated. Psychedelic liability insurance is incredibly expensive and might not cover everything, leaving Optimi vulnerable to devastating legal bills.
• No Patents: Optimi does not own patents on MDMA or magic mushrooms. Instead, they rely on "trade secrets" to protect their recipes. If a competitor figures out how they do things, patent laws won't protect Optimi, and rivals could easily flood the market.

The Bottom Line

Optimi wants to be the company selling the "shovels" in a psychedelic gold rush. While they have a licensed facility and real international sales, their severe cash shortage, heavy government regulations, and lack of patent protection make this IPO an incredibly risky bet.

If you are thinking about investing, make sure you are comfortable with the very real possibility of losing your investment if their cash runs out before the market matures.